June 17, 2024

Clinical Trial Supplies Market Size To Cross USD 4.9 Bn By 2032

The global clinical trial supplies market size accounted for US$ 2.61 Bn in 2022 and is projected to reach around USD 4.9 Bn by 2032, growing at a CAGR of 6.51% from 2023 to 2032.

Clinical Trial Supplies Market Size 2023 To 2032

Report Summary

The global clinical trial supplies market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the clinical trial supplies market across the globe.

A comprehensive estimate on the clinical trial supplies market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of clinical trial supplies during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2777

Clinical Trial Supplies Market Report Scope 

Report CoverageDetails
Market Size in 2023USD 2.78 Billion
Market Size by 2032USD 4.9 Billion
Growth Rate from 2023 to 2032CAGR of 6.51%
Largest MarketNorth America
Fastest Growing MarketAsia Pacific
Base Year2022
Forecast Period2023 to 2032
Segments CoveredBy Phases, By Services, By End User, and By Therapeutic Area
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized clinical trial supplies market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Personal Care Packaging Market Size To Cross USD 61.79 Bn By 2032

Clinical Trial Supplies Market Players

The report includes the profiles of key clinical trial supplies market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • Thermos Fischer Scientific, Inc.
  • Sharp Packaging Services
  • Catalent Pharma Solutions
  • Piramal Pharma Solutions
  • UDG Healthcare
  • PAREXEL International Corporation
  • Almac Group Ltd.
  • Movianto GmbH
  • Patheon, Inc.
  • Biocair International Ltd.
  • PCI Services

Market Segmentation

By Phases

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Services

  • Logistics & distribution
  • Storage & Retention
  • Supply Chain Management
  • Packaging, labeling, and blinding
  • Manufacturing
  • Comparator sourcing

By End User

  • Pharma & Biotech companies
  • Contract Research Organization (CRO)
  • Medical Device Companies

By Therapeutic Area

  • Oncology
  • CNS & mental disorders
  • Cardiovascular
  • Digestive disorders
  • Infectious diseases
  • Metabolic disorders
  • Immunology
  • Blood disorders
  • Other therapeutic areas (dermatological disorders, rare diseases, ENT diseases, Nephrology)

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Clinical Trial Supplies Market 

5.1. COVID-19 Landscape: Clinical Trial Supplies Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Clinical Trial Supplies Market, By Phases

8.1. Clinical Trial Supplies Market, by Phases, 2023-2032

8.1.1. Phase I

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Phase II

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Phase III

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Phase IV

8.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Clinical Trial Supplies Market, By Services

9.1. Clinical Trial Supplies Market, by Services, 2023-2032

9.1.1. Logistics & distribution

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Storage & Retention

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Supply Chain Management

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Packaging, labeling, and blinding

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Manufacturing

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Comparator sourcing

9.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Clinical Trial Supplies Market, By End User 

10.1. Clinical Trial Supplies Market, by End User, 2023-2032

10.1.1. Pharma & Biotech companies

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Contract Research Organization (CRO)

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Medical Device Companies

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Clinical Trial Supplies Market, By Therapeutic Area 

11.1. Clinical Trial Supplies Market, by Therapeutic Area, 2023-2032

11.1.1. Oncology

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. CNS & mental disorders

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Cardiovascular

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Digestive disorders

11.1.4.1. Market Revenue and Forecast (2020-2032)

11.1.5. Infectious diseases

11.1.5.1. Market Revenue and Forecast (2020-2032)

11.1.6. Metabolic disorders

11.1.6.1. Market Revenue and Forecast (2020-2032)

11.1.7. Immunology

11.1.7.1. Market Revenue and Forecast (2020-2032)

11.1.8. Blood disorders

11.1.8.1. Market Revenue and Forecast (2020-2032)

11.1.9. Other therapeutic areas (dermatological disorders, rare diseases, ENT diseases, Nephrology)

11.1.9.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Clinical Trial Supplies Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Phases (2020-2032)

12.1.2. Market Revenue and Forecast, by Services (2020-2032)

12.1.3. Market Revenue and Forecast, by End User (2020-2032)

12.1.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Phases (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Services (2020-2032)

12.1.5.3. Market Revenue and Forecast, by End User (2020-2032)

12.1.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Phases (2020-2032)

12.1.6.2. Market Revenue and Forecast, by Services (2020-2032)

12.1.6.3. Market Revenue and Forecast, by End User (2020-2032)

12.1.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Phases (2020-2032)

12.2.2. Market Revenue and Forecast, by Services (2020-2032)

12.2.3. Market Revenue and Forecast, by End User (2020-2032)

12.2.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Phases (2020-2032)

12.2.5.2. Market Revenue and Forecast, by Services (2020-2032)

12.2.5.3. Market Revenue and Forecast, by End User (2020-2032)

12.2.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Phases (2020-2032)

12.2.6.2. Market Revenue and Forecast, by Services (2020-2032)

12.2.6.3. Market Revenue and Forecast, by End User (2020-2032)

12.2.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Phases (2020-2032)

12.2.7.2. Market Revenue and Forecast, by Services (2020-2032)

12.2.7.3. Market Revenue and Forecast, by End User (2020-2032)

12.2.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Phases (2020-2032)

12.2.8.2. Market Revenue and Forecast, by Services (2020-2032)

12.2.8.3. Market Revenue and Forecast, by End User (2020-2032)

12.2.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Phases (2020-2032)

12.3.2. Market Revenue and Forecast, by Services (2020-2032)

12.3.3. Market Revenue and Forecast, by End User (2020-2032)

12.3.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Phases (2020-2032)

12.3.5.2. Market Revenue and Forecast, by Services (2020-2032)

12.3.5.3. Market Revenue and Forecast, by End User (2020-2032)

12.3.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Phases (2020-2032)

12.3.6.2. Market Revenue and Forecast, by Services (2020-2032)

12.3.6.3. Market Revenue and Forecast, by End User (2020-2032)

12.3.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Phases (2020-2032)

12.3.7.2. Market Revenue and Forecast, by Services (2020-2032)

12.3.7.3. Market Revenue and Forecast, by End User (2020-2032)

12.3.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Phases (2020-2032)

12.3.8.2. Market Revenue and Forecast, by Services (2020-2032)

12.3.8.3. Market Revenue and Forecast, by End User (2020-2032)

12.3.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Phases (2020-2032)

12.4.2. Market Revenue and Forecast, by Services (2020-2032)

12.4.3. Market Revenue and Forecast, by End User (2020-2032)

12.4.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Phases (2020-2032)

12.4.5.2. Market Revenue and Forecast, by Services (2020-2032)

12.4.5.3. Market Revenue and Forecast, by End User (2020-2032)

12.4.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Phases (2020-2032)

12.4.6.2. Market Revenue and Forecast, by Services (2020-2032)

12.4.6.3. Market Revenue and Forecast, by End User (2020-2032)

12.4.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Phases (2020-2032)

12.4.7.2. Market Revenue and Forecast, by Services (2020-2032)

12.4.7.3. Market Revenue and Forecast, by End User (2020-2032)

12.4.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Phases (2020-2032)

12.4.8.2. Market Revenue and Forecast, by Services (2020-2032)

12.4.8.3. Market Revenue and Forecast, by End User (2020-2032)

12.4.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Phases (2020-2032)

12.5.2. Market Revenue and Forecast, by Services (2020-2032)

12.5.3. Market Revenue and Forecast, by End User (2020-2032)

12.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Phases (2020-2032)

12.5.5.2. Market Revenue and Forecast, by Services (2020-2032)

12.5.5.3. Market Revenue and Forecast, by End User (2020-2032)

12.5.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Phases (2020-2032)

12.5.6.2. Market Revenue and Forecast, by Services (2020-2032)

12.5.6.3. Market Revenue and Forecast, by End User (2020-2032)

12.5.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

Chapter 13. Company Profiles

13.1. Thermos Fischer Scientific, Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Sharp Packaging Services

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Catalent Pharma Solutions

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Piramal Pharma Solutions

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. UDG Healthcare

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. PAREXEL International Corporation

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Almac Group Ltd.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Movianto GmbH

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Patheon, Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Biocair International Ltd.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com